Model‐informed precision dosing of vancomycin for rapid achievement of target area under the concentration‐time curve: A simulation study
Clinical and Translational Science · 2023
DOI: 10.1111/cts.13626 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Translational Science, 2023. Verfasst von Kazutaka Oda und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Kumamoto University Hospital, Kumamoto, Japan. Hauptthemen laut MEDLINE: Vancomycin, Anti-Bacterial Agents. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
In this study, we aimed to evaluate limited sampling strategies for achieving the therapeutic ranges of the area under the concentration‐time curve (AUC) of vancomycin on the first and second day (AUC 0–24 , AUC 24–48 , respectively) of therapy. A virtual population of 1000 individuals was created using a population pharmacokinetic (PopPK) model, which was validated and incorporated into our model‐informed precision dosing tool. The results were evaluated using six additional PopPK models selected based on a study design of prospective or retrospective data collection with sufficient concentrations. Bayesian forecasting was performed to evaluate the probability of achieving the therapeutic range of AUC, defined as a ratio of estimated/reference AUC within 0.8–1.2. The Bayesian posterior probability of achieving the AUC 24–48 range increased from 51.3% (a priori probability) to 77.5% after using two‐point sampling at the trough and peak on the first day. Sampling on the first day also yielded a higher Bayesian posterior probability (86.1%) of achieving the AUC 0–24 range compared to the a priori probability of 60.1%. The Bayesian posterior probability of achieving the AUC at steady‐state (AUC SS ) range by sampling on the first or second day decreased with decreased kidney function. We demonstrated that second‐day trough and peak sampling provided accurate AUC 24–48 , and first‐day sampling may assist in rapidly achieving therapeutic AUC 24–48 , although the AUC SS should be re‐estimated in patients with reduced kidney function owing to its unreliable predictive performance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Kumamoto University Hospital, Kumamoto, Japan.
- Department of Infection Control, Kumamoto University Hospital, Kumamoto, Japan.
- Department of Pharmacy, Osaka Medical and Pharmaceutical University Hospital, Osaka, Japan.
- Division of Pharmacodynamics, Keio University Faculty of Pharmacy, Tokyo, Japan.
- Department of Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Toho University, Chiba, Japan.
- Department of Infection Control and Prevention, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan.
ORCID-Profile: Kazutaka Oda, Tomoyuki Yamada, Kazuaki Matsumoto, Takashi Ueda, Hirofumi Jono, Toshimi Kimura
Zitieren
APA
Oda, K., Yamada, T., Matsumoto, K., Hanai, Y., Ueda, T., Samura, M., Shigemi, A., Jono, H., Saito, H., & Kimura, T. (2023). Model‐informed precision dosing of vancomycin for rapid achievement of target area under the concentration‐time curve: A simulation study. Clinical and Translational Science. https://doi.org/10.1111/cts.13626
Vancouver
Oda K, Yamada T, Matsumoto K, Hanai Y, Ueda T, Samura M, et al. Model‐informed precision dosing of vancomycin for rapid achievement of target area under the concentration‐time curve: A simulation study. Clinical and Translational Science. 2023. doi:10.1111/cts.13626
BibTeX
@article{Oda2023,
author = {Oda, Kazutaka and Yamada, Tomoyuki and Matsumoto, Kazuaki and Hanai, Yuki and Ueda, Takashi and Samura, Masaru and Shigemi, Akari and Jono, Hirofumi and Saito, Hideyuki and Kimura, Toshimi},
title = {Model‐informed precision dosing of vancomycin for rapid achievement of target area under the concentration‐time curve: A simulation study},
journal = {Clinical and Translational Science},
year = {2023},
doi = {10.1111/cts.13626}
}
EUVIMED